Ge­nomics + ma­chine learn­ing = com­pa­ny's strat­e­gy to speed up hos­pi­tal di­ag­nos­tics and iden­ti­fy an­tibi­ot­ic re­sis­tance

Day Ze­ro Di­ag­nos­tics has been fo­cused on com­bin­ing genome se­quenc­ing and ma­chine learn­ing to di­ag­nose in­fec­tious dis­eases. And now the di­ag­nos­tics play­er has net­ted its biggest fi­nanc­ing round yet.

Com­pa­ny ex­ecs an­nounced ear­li­er this week that the biotech net­ted $21 mil­lion in a ven­ture eq­ui­ty fi­nanc­ing round lead by Sands Cap­i­tal. Oth­er in­vestors tagged on as well, in­clud­ing the back­ing of big med-tech com­pa­ny BD (Bec­ton, Dick­in­son and Com­pa­ny) and Hongk­ou Cap­i­tal as new in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER